Shanghai MicroPort Endovascular MedTech Co., Ltd. (688016.SS)
CNY 84.47
(0.86%)
CNY 84.47
(0.86%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 344.75 Million CNY | 36.54% |
| 2022 | 252.49 Million CNY | 9.08% |
| 2021 | 231.47 Million CNY | 62.9% |
| 2020 | 142.09 Million CNY | 58.34% |
| 2019 | 89.73 Million CNY | 70.41% |
| 2018 | 52.66 Million CNY | 45.29% |
| 2017 | 36.24 Million CNY | -44.43% |
| 2016 | 65.21 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 438.46 Million CNY | 27.18% |
| 2024 Q2 | 404.45 Million CNY | -7.76% |
| 2024 Q3 | 637.69 Million CNY | 57.67% |
| 2023 Q4 | 344.75 Million CNY | 13.56% |
| 2023 FY | 344.75 Million CNY | 36.54% |
| 2023 Q3 | 303.58 Million CNY | -6.25% |
| 2023 Q2 | 323.81 Million CNY | 12.27% |
| 2023 Q1 | 288.42 Million CNY | 14.23% |
| 2022 Q4 | 252.49 Million CNY | 22.56% |
| 2022 Q3 | 206 Million CNY | -45.96% |
| 2022 Q2 | 381.22 Million CNY | 54.51% |
| 2022 Q1 | 246.73 Million CNY | 6.59% |
| 2022 FY | 252.49 Million CNY | 9.08% |
| 2021 FY | 231.47 Million CNY | 62.9% |
| 2021 Q1 | 200.06 Million CNY | 40.79% |
| 2021 Q2 | 196.71 Million CNY | -1.67% |
| 2021 Q3 | 207.69 Million CNY | 5.58% |
| 2021 Q4 | 231.47 Million CNY | 11.45% |
| 2020 Q1 | 99.7 Million CNY | 11.1% |
| 2020 Q4 | 142.09 Million CNY | 22.96% |
| 2020 Q3 | 115.55 Million CNY | 20.95% |
| 2020 Q2 | 95.53 Million CNY | -4.17% |
| 2020 FY | 142.09 Million CNY | 58.34% |
| 2019 Q4 | 89.73 Million CNY | 18.18% |
| 2019 Q3 | 75.93 Million CNY | -3.66% |
| 2019 FY | 89.73 Million CNY | 70.41% |
| 2019 Q1 | 86.2 Million CNY | 63.69% |
| 2019 Q2 | 78.81 Million CNY | -8.56% |
| 2018 Q4 | 52.66 Million CNY | 0.0% |
| 2018 FY | 52.66 Million CNY | 45.29% |
| 2017 FY | 36.24 Million CNY | -44.43% |
| 2016 FY | 65.21 Million CNY | 0.0% |